Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

What this study is testing ClinicalTrials.gov NCT05933499 ↗

Description as written by the study sponsor.

In adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and insulin levels, reducing resting metabolic rate, and increasing the risk of falls and fractures. Data in animals and humans suggest that bimagrumab, an investigational new drug for obesity that inhibits the activin type II receptor (ActRII) inhibitor, may help maximize loss of fat mass while maintaining muscle mass when used in combination with a glucagon-like peptide 1 receptor agonist (GLP-1 RA). The investigators hypothesize that in a randomized, placebo-controlled trial of 63 adults with obesity randomized to tirzepatide (GLP-1/GIP RA) + bimagrumab, tirzepatide alone, or bimagrumab alone, the combination of tirzepatide + bimagrumab will result in improvements in muscle, fat, and bone compared to tirzepatide alone or bimagrumab alone when given in addition to a lifestyle intervention for weight loss over 52 weeks.

Treatments tested

• Bimagrumab Drug

  SQ bimagrumab 300mg qweek

• Tirzepatide Drug

  SQ tirzepatide 15mg qweek

• Calcium/Vitamin D Dietary supplement

  Elemental calcium 1200 mg + vitamin D3 800 IU PO daily

• Lifestyle and nutrition counseling Behavioral

  Lifestyle and nutrition counseling consistent with current guidelines for weight management